Skip to main content

Security report for chiesigroup.com

Chiesi Farmaceutici S.p.A. · Healthcare · Italy

Medium risk. 3 critical or high findings in GDPR outside view, SSL/TLS and 1 other check.

Security score

67/100

Risk levelMedium

0–100, higher is better. How it is calculated

Chiesi Farmaceutici S.p.A. is a well-established international bio-pharmaceutical company based in Italy, specializing in innovative therapeutic solutions for respiratory health, rare diseases, and specialty care. The company emphasizes research-driven innovation and sustainability, holding a B Corp certification that underscores its commitment to social and environmental responsibility. The website reflects a professional and comprehensive digital presence, targeting patients, healthcare professionals, and partners with clear, relevant content and accessible navigation. Technically, the website employs modern web technologies including Bootstrap for responsive design, Swiper for interactive sliders, and Matomo for analytics, complemented by OneTrust for cookie consent management. The site demonstrates good mobile optimization, accessibility, and SEO practices, although some security headers could be enhanced. HTTPS is enforced, ensuring secure communications. From a security perspective, the site shows a solid posture with no evident vulnerabilities or exposed sensitive data. However, the absence of a published security policy, incident response contacts, and vulnerability disclosure mechanisms suggests areas for improvement. The WHOIS data for the domain is unavailable, likely due to privacy protection, which slightly reduces transparency but does not detract significantly from the site's legitimacy given the strong brand presence and consistent content. Overall, the website is trustworthy, professionally maintained, and compliant with privacy regulations such as GDPR. Strategic recommendations include enhancing security headers, publishing security policies, and establishing formal vulnerability disclosure channels to further strengthen trust and security maturity.

Scanned

NIS2 and GDPR posture

GDPR outside view
73/ 100 · Medium
Checks completed
7of 7

NIS2 Art. 21(2)

  1. (a) Risk analysis and security policies: Not visible from outside
  2. (b) Incident handling: One indicator
  3. (c) Business continuity, backups and crisis management: Not visible from outside
  4. (d) Supply chain security: Not visible from outside
  5. (e) Secure acquisition, development and maintenance, including vulnerability handling: Partly checked
  6. (f) Assessing the effectiveness of security measures: Not visible from outside
  7. (g) Cyber hygiene and security training: Not visible from outside
  8. (h) Cryptography and encryption: Partly checked
  9. (i) HR security, access control and asset management: One indicator
  10. (j) Multi-factor authentication and secured communications: Not visible from outside

This scan rated NIS2 with an earlier keyword method that is no longer shown; rescan for the per-article view. Risk management, continuity, supply chain, training, MFA, management oversight (Art. 20) and incident reporting (Art. 23) need internal evidence, and Guard cannot tell whether NIS2 applies to this organisation.

GDPR is indicative only, based on publicly visible signals: Articles 7, 12, 13 and 32 of Regulation (EU) 2016/679 and Article 5(3) of the ePrivacy Directive. Not a certification or legal assessment.

Priority findings

3 findings rated critical or high. Fix these first.

  1. GDPR outside view

    These are the privacy signals visitors and data protection authorities look for under GDPR.

    • High

      No Cookie Consent Banner found

      GDPR requires explicit consent for non-essential cookies

      What to do: Implement a cookie consent banner that appears on first visit

  2. SSL/TLS

    TLS encrypts the connection and proves the site is really yours. Weak or expiring certificates trigger browser warnings and put traffic at risk.

    • High

      Weak Protocols Supported

      Server supports weak protocols: TLSv1.1

      What to do: Disable TLS 1.0, TLS 1.1, and all SSL versions

      • CWE-327
      • OWASP A04:2025
      • ASVS V12.1.1

  3. Network security

    Services reachable from the internet are the first thing attackers probe. Anything open that does not need to be should be closed.

    • High

      High-Risk Service Exposed: FTP

      Port 21 (FTP) is publicly accessible - FTP - Often unencrypted file transfer

      What to do: Consider restricting access to FTP or implementing strong authentication

      • NIS2 21(2)(e)
      • IR 2024/2690 6.7.2(f): Implementing Regulation (EU) 2024/2690, Annex point 6.7.2(f): Network security
      • NIST CM-7: NIST SP 800-53 Rev. 5 CM-7: Least Functionality
      • NIST SC-7: NIST SP 800-53 Rev. 5 SC-7: Boundary Protection

Need hands-on remediation? Email guard@offseq.com

Keep watching chiesigroup.com

This scan found 16 issues across 6 checks. Monitoring re-runs those checks daily, emails you when something material changes and records each fix, so you can show progress.

Daily monitoring

Recommended

€25per month

  • TLS certificates and expiry
  • DNS records
  • SPF, DKIM and DMARC
  • Security headers
  • GDPR and NIS2 posture
  • Exposed services
  • Third-party trackers
  • Security score drift

Email alerts on material changes and an exportable JSON history of every change.

Billed monthly to your card. Cancel anytime. The full timeline opens with your unlock code.

Full report

€39.90one-time

  • The complete analysis as a PDF you can cite
  • Email delivery with an unlock code
  • Lifetime access to this report

Prices incl. 21% VAT. Secure checkout by Mollie; sold by SEQ SIA, Latvia.

Results by check

Each check with its score, findings and the evidence it collected.

How this score is calculated

The security score runs 0–100, higher is better. It is the plain average of the security checks that completed in this scan, each counted equally. A check that could not run is left out: it counts neither as a pass nor as a fail.

Counted in this score

SSL/TLS
62
Security headers
95
Email security
80
DNS health
70
Network security
20
GDPR outside view
73
Average
67

Not counted

  • NIS2 outside view: Re-weights evidence from the TLS, email, DNS, network and hygiene checks, so counting it would count that evidence twice. Shown on its own.
  • OffSeq Observations: An AI reading of the site, useful context but not reproducible evidence. Shown on its own.

Findings that cap the score at 49

Each of these is serious on its own, so while any is present the site cannot rate better than high risk, however good the other checks are.

  • The certificate is not trusted by browsers
  • The website is not served over HTTPS
  • A database, remote desktop, file-sharing or Telnet service is reachable from the internet
  • The page loads a script from a compromised source
  • The domain registration has expired
  • SPF authorises every server to send mail as the domain

Partial scans

When the site blocks Guard or most checks cannot run, the score covers only the checks that ran (usually DNS and email), is capped at 75 and is shown as partial, without a risk level.

Risk levels

  • Critical0–25
  • High26–49
  • Medium50–75
  • Low76–100

Technical appendix

Business context, site observations and technical notes gathered during the scan, and the standards behind each reference.

Business context

Business profile

Chiesi operates in the competitive pharmaceutical sector with a focus on research and development of therapies for respiratory conditions, rare diseases, and specialty care. The company leverages its long history since 1935 and B Corp certification to position itself as a responsible and innovative leader. Its business model centers on developing and commercializing high-value therapeutic solutions, supported by a global network of partnerships and subsidiaries. The website's content and linked domains indicate a robust ecosystem including clinical trials, foundations, and career portals, reflecting a mature and diversified operation. Growth indicators include recent acquisitions and pipeline expansions. The company targets healthcare providers, patients, and scientific communities, emphasizing sustainability and patient-centric innovation.

Security posture

The website demonstrates a mature security posture with enforced HTTPS and cookie consent mechanisms aligned with GDPR requirements. No critical vulnerabilities or exposed sensitive information were detected in the HTML content. However, the absence of key security headers such as Content-Security-Policy and Strict-Transport-Security represents an opportunity for improvement. Additionally, no public security policy or incident response contact information is available, which could hinder effective communication during security incidents. The lack of a vulnerability disclosure program or security.txt file limits transparency and community engagement in security matters. Overall, the site is secure but could benefit from enhanced security governance and communication practices.

Recommendations

  1. Implement comprehensive security headers including Content-Security-Policy, X-Content-Type-Options, and Strict-Transport-Security to harden the website against common attacks.
  2. Publish a clear security policy and provide dedicated incident response contact channels to improve transparency and readiness.
  3. Establish a vulnerability disclosure program and host a security.txt file to encourage responsible reporting of security issues.
  4. Regularly audit and update third-party libraries and scripts to mitigate risks from vulnerable components.
  5. Enhance monitoring and logging capabilities to detect and respond to security incidents promptly.

Contact details published on the site

Addresses
Legal name
Chiesi Farmaceutici S.p.A.
Site observations

Automated reading of the public site. Ratings are indicative.

Business

Company
Chiesi Farmaceutici S.p.A.
Description
Siamo un gruppo biofarmaceutico orientato alla ricerca che sviluppa e commercializza soluzioni terapeutiche innovative per la salute respiratoria, le malattie rare e le cure specialistiche.
Key services
Respiratory health solutions, Rare diseases treatments, Specialty care products
Content quality
excellent
Branding
consistent

Technology

Stack
Bootstrap, Swiper, Plyr, Select2, SweetAlert2, Matomo Analytics, OneTrust Cookie Consent
Frameworks
Bootstrap
Performance
moderate
Mobile
good
Accessibility
good
SEO
good

Security

Observed score
85/100
Good practices seen
  • HTTPS enforced
  • Cookie consent mechanism implemented
  • No exposed sensitive data in HTML

Analytics and tracking

Services
Matomo
Tracking level
moderate
Privacy practices
good

Advertising

Tracking pixels
Matomo
Marketing tools
OneTrust Cookie Consent
Transparency
good

Site quality

Design
excellent
User experience
excellent
Content relevance
excellent
Navigation
excellent
Professionalism
excellent
Trustworthiness
high

Key observations

  1. Website is fully accessible with rich content and professional design.
  2. Strong focus on pharmaceutical research and patient care.
  3. Comprehensive cookie and privacy consent mechanisms implemented.
  4. No visible security policy or incident response contact found.
  5. WHOIS data is unavailable, indicating privacy protection or registry issue.
  6. Use of modern web technologies and analytics tools.
  7. No suspicious or malicious content detected.
Technical notes

Notes

The website is built on a modern technology stack featuring Bootstrap for responsive design, Swiper for interactive elements, and Matomo for privacy-focused analytics. It integrates OneTrust for cookie consent management, demonstrating compliance with privacy regulations. The site shows good mobile optimization and accessibility features, with semantic HTML and ARIA labels. Performance is moderate, with potential for optimization in loading times and resource management. No CMS was explicitly detected, suggesting a custom or proprietary platform. Hosting details are not disclosed. The technical implementation supports a professional user experience but could be enhanced with additional security headers and performance tuning.
Standards and sources

Reference chips under each finding point to the standard, regulation or specification the finding relates to. They are taken from the official datasets below and mapped conservatively: a finding with no defensible link shows none. NIS2 and GDPR references mark where a finding is relevant evidence, not a compliance verdict. Implementing Regulation (EU) 2024/2690 binds digital infrastructure and digital service providers; for other entities it is the most detailed public reading of the Article 21 measures. WCAG, EN 301 549, European Accessibility Act and Web Accessibility Directive references name the requirement an automated accessibility rule relates to; they are not a conformance verdict.

Retrieved 2026-10-25

Reviews of this site

Share your experience with chiesigroup.com. Every review is verified by email and published after moderation.

Overall rating
Select a rating
4000 characters remaining

We’ll email you to confirm your review and keep your details private.

Community rating

No published reviews yet. Be the first to review chiesigroup.com.

Feedback on this report

Rate this report, add an optional comment, and tell us if you want a security specialist to follow up.

Overall report quality
Select a rating
2000 characters remaining

We only use your feedback to improve Guard reports. Contact details are never shared.